35例前庭阵发症患者治疗前后生活质量评估

罗丽霞; 黎景佳; 叶虹; 李卓卫; 龚汉贤; 杨晓洁

doi:10.13201/j.issn.1001-1781.2016.21.012

35例前庭阵发症患者治疗前后生活质量评估

- 1 南方医科大学附属南海人民医院神经内科(广东佛山, 528000);
- 2 佛山市第一人民医院耳鼻咽喉头颈外科
基金项目:
广东省科技计划项目公益研究与能力建设专项(No:2014A020212075)

广东省自然科学基金自由申请项目(No:2016A030313245)

详细信息

通讯作者: 黎景佳,E-mail:li_jingjia@163.com

中图分类号: R764.3

收稿日期: 2016-08-21

The effect of topiramate or carbamazepine treatment on the quality of life in patients with vestibular paroxysmia

- 1 Department of Neurology, the Affiliated Nanhai People's Hospital of Southern Medical University, Foshan, 528000, China;
- 2 Department of Otolaryngology-Head and Neck Surgery, the First People's Hospital of Foshan

More Information

Corresponding author: LI Jingjia, E-mail: li_jingjia@163.com

Received Date: 21 August 2016

摘要

摘要: 目的:研究前庭阵发症(VP)患者抗癫痫药物治疗前后生活质量(QOL)的变化。方法:选取2012-09-2015-09期间在神经内科门诊就诊的35例VP患者,采用SF-36健康调查量表(SF-36)和眩晕障碍量表(DHI)对患者的QOL进行调查与评估.统计分析治疗前后QOL的改变。结果:VP患者接受抗癫痫药物治疗1个月后,SF-36量表中生理功能、生理职能、总体健康、活力、社会功能和情感职能等6个维度评分较治疗前明显提高,差异有统计学意义(P<0.01);DHI量表中的情感、功能、躯体评分和三项总分较治疗前明显降低,差异有统计学意义(P<0.01)。结论:抗癫痫药物可明显改善VP患者的QOL,SF-36和DHI量表能有效评估VP患者的QOL。
- 前庭阵发症 /
- 卡马西平 /
- 生活质量 /
- 眩晕障碍量表
Abstract: Objective: To study the effect of topiramate or carbamazepine treatment on the quality of life (QOL) in patients with vestibular paroxysmia(VP).Method: Thirty-five cases diagnosed as VP from September 2012 to September 2015 were retrospectively studied. Medical outcomes study short form(SF-36)and the dizziness handicap inventory(DHI) were used to analyze the QOL.Result: After topiramate or carbamazepine treatment for one month, the scores of physical function, role physical, general health, vitality, social functioning, role emotional in SF-36 were significantly increased than pre-treatment(P<0.01); and the scores of emotion, function and physiology in DHI were significantly decreased than pre-treatment(P<0.01).Conclusion: Topiramate and carbamazepine may obviously improve the QOL of VP patients.The SF-36 and DHI scales could reflect the change of QOL in VP patients.
- vestibular paroxysmia /
- carbamazepine /
- quality of life /
- dizziness handicap inventory

HTML全文

参考文献(12)

[1]	BRANDT T,STRUPP M,DIETERICH M.Vestibular paroxysmia:a treatable neurovascular cross-compression syndrome[J].J Neurol,2016,263:90-96.
[2]	HVFNER K,BARRESI D,GLASER M,et al.Vestibular paroxysmia:diagnostic features and medical treatment[J].Neurology,2008,71:1006-1014.
[3]	李鲁,王红妹,沈毅.SF-36健康调查量表中文版的研制及其性能测试[J].中华预防医学杂志,2002,36(2):109-113.
[4]	左丽静,刘博.眩晕患者的生活质量评估[J].临床耳鼻咽喉头颈外科杂志,2009,23(4):190-192.
[5]	NEUHAUSER H K,VON BREVERN M,RADTKE A,et al.Epidemiology of vestibular vertigo:a neurotologic survey of the general population[J].Neurology,2005,65:898-900.
[6]	MELI A,ZIMATORE G,BADARACCO C,et al.Effects of vestibular rehabilitation therapy on emotional aspects in chronic vestibular patients[J].J Psychosom Res,2007,63:185-190.
[7]	NAGARATNAM N,IP J,BOUHAIDAR P.The vestibular dysfunction and anxiety disorder interface:a descriptive study with special reference to the elderly[J].Arch Gerontol Geriatr,2005,40:253-264.
[8]	FURMAN J M,JACOB R G.A clinical taxonomy of dizziness and anxiety in the otoneurological setting[J].J Anxiety Disord,2001,15:9-26.
[9]	郭向东,王庆林,李莹,等.良性阵发性位置性眩晕治疗前后生活质量研究[J].临床耳鼻咽喉头颈外科杂志,2011,25(16):729-731.
[10]	修世国,刑东升,胡玮,等.眩晕障碍量表在BPPV患者生活质量评估中的应用[J].听力学及言语疾病杂志,2014,22(1):48-50.
[11]	孔维佳,刘波,冷样名.眩晕疾病的个体化综合治疗[J].临床耳鼻咽喉头颈外科杂志,2008,22(4):145-150.
[12]	OBERMANN M,BOCK E,SABEV N,et al.Long-term outcome of vertigo and dizziness associated disorders following treatment in specialized tertiary care:the dizziness and vertigo registry (DiVeR) study[J].J Neurol,2015,262:2083-2091.